Princeton, NJ, United States of America

Haiqing Wang

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Haiqing Wang. Retrieved from https://idiyas.com/inventor/haiqing-wang-7641lb75

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Haiqing Wang

Introduction

Haiqing Wang is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic methods.

Latest Patents

Wang holds a patent for the "Treatment of cancer with anti-GITR agonist antibodies." This patent outlines methods for treating cancer by administering a therapeutically effective amount of an anti-GITR antibody, either alone or in combination with an anti-PD-1 or anti-PD-L1 antibody. His work in this area is crucial for advancing cancer therapies.

Career Highlights

Wang is currently associated with Bristol-Myers Squibb Company, where he continues to contribute to groundbreaking research in oncology. His expertise and dedication to improving cancer treatment options have made him a valuable asset to the company.

Collaborations

Wang collaborates with esteemed colleagues, including Suba Krishnan and Penny E. Phillips. Their combined efforts in research and development enhance the potential for innovative cancer therapies.

Conclusion

Haiqing Wang's contributions to cancer treatment through his patent and work at Bristol-Myers Squibb Company highlight his role as a leading inventor in the field. His innovative approaches are paving the way for more effective cancer therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…